 - Novel platform allows co-targeting of iNKT cells and tumor antigens in a single product- Trial marks the first milestone in a comprehensive clinical development plan to evaluate iNKT agonists to improve outcomes in a variety of solid tumors Westport, Connecticut--Newsfile Corp. - April 8, 2021 - Portage Biotech Inc. NASDAQ: PRTG CSE: PBT.U Portage or... 